开云app官网登录入口网页版-官方正版

#binimetinib#

9篇内容 | 1009人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1665208, encodeId=1e1016652082f, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, objectType=article, longId=734132, objectId=690de34132b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=690de34132b5, replyNumber=0, likeNumber=73, createdTime=2023-04-02, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=690de34132b5, moduleTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=690de34132b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665206, encodeId=08de1665206ad, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, objectType=article, longId=206081, objectId=4595206081b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4595206081b2, replyNumber=0, likeNumber=71, createdTime=2021-11-10, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4595206081b2, moduleTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4595206081b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665205, encodeId=e819166520563, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle= J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效, objectType=article, longId=199949, objectId=9c171999498a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c171999498a, replyNumber=0, likeNumber=72, createdTime=2020-12-17, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c171999498a, moduleTitle= J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9c171999498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665207, encodeId=048b166520ead, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle=低级别浆液性卵巢癌：Binimetinib疗效有待进一步验证, objectType=article, longId=206093, objectId=85bc20609347, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85bc20609347, replyNumber=0, likeNumber=62, createdTime=2021-12-05, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85bc20609347, moduleTitle=低级别浆液性卵巢癌：Binimetinib疗效有待进一步验证, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=85bc20609347)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665204, encodeId=14041665204c3, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle=NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌, objectType=article, longId=181909, objectId=dfaf18190961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfaf18190961, replyNumber=0, likeNumber=101, createdTime=2020-09-10, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfaf18190961, moduleTitle=NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dfaf18190961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665202, encodeId=d49c16652024c, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle=Lancet oncol：Encorafenib联合binimetinib治疗BRAF突变型黑色素瘤总体存活率效益显著, objectType=article, longId=148780, objectId=15b2148e8062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15b2148e8062, replyNumber=0, likeNumber=105, createdTime=2019-06-13, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15b2148e8062, moduleTitle=Lancet oncol：Encorafenib联合binimetinib治疗BRAF突变型黑色素瘤总体存活率效益显著, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=15b2148e8062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665203, encodeId=688a1665203fb, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle=CLIN CANCER RES：Binimetinib联合紫杉醇治疗铂类耐药卵巢癌, objectType=article, longId=154015, objectId=f65015401548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f65015401548, replyNumber=0, likeNumber=65, createdTime=2019-07-17, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f65015401548, moduleTitle=CLIN CANCER RES：Binimetinib联合紫杉醇治疗铂类耐药卵巢癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f65015401548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665201, encodeId=30fb16652013a, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle=Lancet：黑色素瘤新药binimetinib与达卡巴嗪临床研究, objectType=article, longId=91539, objectId=570491539a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=570491539a0, replyNumber=0, likeNumber=109, createdTime=2017-12-13, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=570491539a0, moduleTitle=Lancet：黑色素瘤新药binimetinib与达卡巴嗪临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=570491539a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1665200, encodeId=60ec166520086, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, objectTitle=Array BioPharma从诺华手中收回肿瘤药binimetinib授权, objectType=article, longId=43726, objectId=c1da43e26eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da43e26eb, replyNumber=0, likeNumber=55, createdTime=2015-04-11, rootId=0, userName=12498e0fm86暂无昵称, userId=7f1a25912110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da43e26eb, moduleTitle=Array BioPharma从诺华手中收回肿瘤药binimetinib授权, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c1da43e26eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

binimetinib

2020-05-29

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益

2023-04-02

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益

2021-11-10

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

J Clin Oncol：MEK1/2抑制剂Binimetinib治疗低级别浆液性卵巢癌的疗效

2020-12-17

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

低级别浆液性卵巢癌：Binimetinib疗效有待进一步验证

2021-12-05

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌

2020-09-10

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

Lancet oncol：Encorafenib联合binimetinib治疗BRAF突变型黑色素瘤总体存活率效益显著

2019-06-13

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

CLIN CANCER RES：Binimetinib联合紫杉醇治疗铂类耐药卵巢癌

2019-07-17

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

Lancet：黑色素瘤新药binimetinib与达卡巴嗪临床研究

2017-12-13

12498e0fm86暂无昵称 (审核中...)

前往app查看评论内容

#binimetinib#

Array BioPharma从诺华手中收回肿瘤药binimetinib授权

2015-04-11

科室
- - 订阅+
  - 更多科室
工具
服务